Web Research
Web Research — Anthem Biosciences
The Bottom Line from the Web
The single most important thing the web reveals that the filings did not yet anchor: Anthem just printed a blowout Q4FY26 on the eve of this report (results approved 19 May 2026; conference call 20 May), with PAT surging 129.8% YoY to ₹189.8 cr and EBITDA margin spiking to 48.1% — putting the FY26 cut-to-mid-teens guidance behind the company and resetting the analyst conversation. Layered on top, the company is mid-governance-test: lead pre-IPO PE backer True North (via Viridity Tone LLP) exited its remaining 3.6% stake on 9 March 2026 for ₹1,317 cr in a single bulk deal, which mechanically triggers a ₹127.68 cr "upside-sharing" cash payment from the company to the three founder-promoters — contingent on a public-shareholder vote at the 22 July 2026 AGM. Meanwhile, three designated-person insider-trading code violations in five weeks (Oct–Nov 2025), the General Counsel's exit after 19 years (13 March 2026), and an auditor rotation to S.R. Batliboi (EY India) all suggest a management team under unusual governance scrutiny in its first nine months as a listed company.
What Matters Most
The findings below are ordered by how much each one shifts the investment view. Every item cites a source URL.
1. Q4FY26 results just blew the doors off — PAT +130%, margin to 48%
Reported 19 May 2026 (call on 20 May). Consolidated Q4 revenue ₹610.9 cr (+26.4% YoY, +44.4% QoQ from a depressed Q3), PAT ₹189.8 cr vs ₹82.6 cr (+129.8%), EBITDA ₹318.4 cr at 48.1% margin vs 40.4% prior year. Full-year FY26 revenue ₹2,124 cr (+15.2%), PAT ₹591.8 cr (+31.1%), EBITDA ₹989.6 cr at 46.6% margin. Net cash ₹1,374 cr. Source: scanx.trade; marketscreener.com.
Q4 came in materially above the mid-teens FY26 trajectory implied by Q3 guidance and reverses the destocking narrative. Sequential 8 pp EBITDA margin lift is the structurally important read; management's "20%+ growth aspiration" now has a fresh proof point heading into FY27.
2. True North / Viridity Tone exit triggered ₹127.68 cr promoter "upside-sharing" payout — going to a shareholder vote
On 9 March 2026, Viridity Tone LLP sold its entire remaining stake of 20.3 million shares for ₹1,317 cr in a bulk deal on BSE. Under a 1 March 2021 Shareholders' Agreement (amended 30 December 2024), once Viridity's lifetime return crosses the higher of 25% IRR or 2x cost, the excess is "shared" with the three founder-promoters — Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa. The Board (22 April 2026) approved a ₹127.68 cr cash payment to those promoters and is putting it to public-shareholder ordinary resolution at the 20th AGM (22 July 2026), with related parties abstaining. Sources: scanx.trade upside-sharing arrangement; whalesbook.com promoter payout.
This is unusual: it is a post-listing cash transfer from the company's treasury to the founders, triggered by a private-equity exit at a price the public market also paid. The vote outcome is the single most material near-term governance test — a high-dissent result would re-rate alignment. Note: the Q4 result and dividend announcement were timed two months before the vote.
3. Three insider-trading code violations in five weeks (Oct–Nov 2025)
On 28 October 2025, Anthem disclosed one designated person traded during a closed window; on 11 November 2025, the company disclosed two more designated persons caught for trading during closed windows or without prior approval. Warning letters issued in all cases. Source: scanx.trade insider trading violations Nov 2025; whalesbook.com trading window closure 2026-03-27.
Three breaches in 35 days, by name-protected designated persons, in a freshly-listed company is not a rounding error in SEBI's eyes. The company's own subsequent Q4 trading-window closure notice explicitly cites these "recurring issues" as a "potential concern regarding adherence to trading regulations among key personnel." Watch for any SEBI follow-up.
4. Citi initiates Buy at ₹870; consensus is 7 Buys / 0 Hold / 0 Sell
Citi initiated coverage on 21 April 2026 with a ₹870 target (17% upside from then-current ₹744), modeling 26% FY23–FY26 revenue CAGR and 19%/22% revenue/EBITDA CAGR for FY26–FY28, with 150–200 bps medium-term margin expansion from backward integration. JPMorgan upgraded to Buy at ₹790 (9 February 2026). Nomura initiated Buy at ₹740 (28 November 2025). 7 analysts now cover the stock; average 12-month target ₹786.86 (range ₹720–₹870); consensus is Strong Buy. Citi places Anthem "alongside Divi's Laboratories" as preferred picks. Sources: investing.com analyst ratings; etnownews.com Citi initiation.
The stock at ₹780.50 already sits 0.8% below the consensus mean target — meaning the Street is fully on side, but there is no built-in upside in the consensus number unless estimates start moving up post-Q4.
5. Auditor rotation: K.P. Rao & Co. → S.R. Batliboi & Associates LLP (EY India)
Board approved 22 April 2026. K.P. Rao & Co. (a small Bengaluru firm) signed the FY26 results with an unmodified opinion and will exit after the 20th AGM (FY26–27). Incoming: S.R. Batliboi & Associates LLP (EY India, Firm Reg. No. 101049W/E300004), 5-year term FY26-27 to FY31-32. Source: scanx.trade auditor change.
Moving to a Big Four affiliate is governance-positive for an issuer where the RHP previously flagged "cash flow disconnects and subsidiary loans" and where SEBI insider-trading code violations are recurring. K.P. Rao audited through Anthem's listing year; the transition signals upgraded oversight just before FY27.
6. BIOSECURE Act re-introduced (S.3469) and bundled into 2026 NDAA Senate version
The BIOSECURE Act of 2025 was introduced in the US Senate on 12 November 2025 (S.3469) and included in the Senate version of the FY2026 National Defense Authorization Act, with up to three years for OMB/FAR implementation and a five-year grandfathering window for existing CDMO contracts. The bill blocks US federal procurement of "biotechnology equipment or services" from "biotechnology companies of concern" (WuXi AppTec, BGI, MGI, Complete Genomics, WuXi Biologics named). Sources: Hogan Lovells BIOSECURE in NDAA; Congress.gov S.3469.
This is the single largest exogenous tailwind for the Indian CRDMO peer set. Even with five-year grandfathering, sponsors with new programs are already pre-qualifying alternatives — RFQ activity at Anthem improved per Q3 commentary. Passage timing is the variable.
7. Citi's earnings model: 19% revenue / 22% EBITDA CAGR FY26–FY28
Citi expects four key drivers — recovery in volumes of legacy molecules, ramp of newly commercialized molecules, Semaglutide/Peg-Filgrastim traction in specialty ingredients, and 150–200 bps margin expansion from backward integration / operating leverage. Twelvedata consensus (7 analysts): FY27E revenue ₹2,548 cr (+20%); FY28E revenue ₹3,038 cr (+19%); FY27E EPS ₹12.36; FY28E EPS ₹14.89 — with 1 down-revision in the last 30 days, no up-revisions, suggesting estimates may move higher post-Q4. Source: Twelvedata earnings & revenue estimates.
8. ₹275 cr Neoanthem loan-to-equity conversion (23 February 2026)
Anthem executed a First Amendment to its loan agreement with wholly-owned subsidiary Neoanthem Lifesciences Pvt Ltd, converting an additional ₹275 cr of intercompany loan into equity shares. Two weeks earlier (7 January 2026), Anthem also issued a ₹49 cr corporate guarantee for Neoanthem's working-capital facility with Federal Bank (existing charge ₹214 cr from 1 June 2022). Sources: tradebrains.in Neoanthem conversion; whalesbook.com Neoanthem 275 cr.
Neoanthem (Unit III greenfield) remains in early-stage ramp and continues to absorb parent capital. The structure is now: parent equity + parent guarantee on Neoanthem's bank line. Watch the FY26 standalone P&L for interest income previously earned on the intercompany loan — this conversion eliminates that line.
9. Unit 4 (Harohalli) Phase I capex upsized to ₹1,200 cr — over two years
Confirmed in Q4FY26 release: Phase I investment ₹12,000 mn (₹1,200 cr) at the new Harohalli greenfield. Original Q3 guidance was ₹1,000 cr over two years. Scope: small molecule manufacturing, peptides (incl. GLP-1 backward integration), fermentation, oligonucleotides. Source: scanx.trade Q4 release Unit 4 ₹12,000 mn.
10. General Counsel K. Ramakrishnan resigned after 19 years (effective 31 March 2026)
Announced 13 March 2026 — four days after the Viridity Tone block deal and one month after the Neoanthem ₹275 cr conversion. Reason not publicly disclosed. Source: scanx.trade Ramakrishnan resignation.
11. Domestic institutions stepped in as foreigners stepped out
Shareholding pattern shifted materially over Q3–Q4FY26: DII holding 7.21% (Sep'25) → 11.55% (Mar'26); FII 1.66% → 1.28%; public 16.42% → 12.48%; promoters held flat at 74.67%. Number of shareholders fell from 217,681 to 180,220 (post-IPO consolidation). Top external holders include Viridity Tone LLP (3.80% at IPO listing, now zero), Portsmouth Technologies (2.74%), Swara/Keerthi Trusts (1.02% each), Kotak AMC (0.85%), Axis AMC (0.48%). Source: screener.in shareholding; investing.com ownership.
12. First-ever dividend: ₹2.00/share final (FY26)
Board recommended ₹2.00 per share final dividend for FY26 at the 19 May 2026 meeting; ex-date 25 June 2026 per MarketScreener calendar. On standalone net profit of ₹670.6 cr, the payout ratio is roughly 16.8%. Source: scanx.trade FY26 dividend.
Recent News Timeline
What the Specialists Asked
Governance and People Signals
The first nine months as a listed company have been governance-active. Three threads need to be tracked together rather than in isolation.
Designated-person insider-trading code violations. Three separate incidents in five weeks (28 Oct 2025; 11 Nov 2025 — two persons same disclosure). The company itself, when announcing the Q4 trading-window closure on 27 March 2026, said the violations "highlight a potential concern regarding adherence to trading regulations among key personnel." Action taken to date: warning letters. Source: whalesbook.com window closure.
Promoter upside-sharing arrangement. A 2021-vintage Shareholders' Agreement, amended December 2024, gives the three founder-promoters an upside share once True North (Viridity Tone) crosses 25% IRR or 2x cost on its exit. Viridity exited on 9 March 2026 at ₹1,317 cr; the company will pay the three founders ₹127.68 cr in cash subject to a public-shareholder vote on 22 July 2026. Note: the auditor change to S.R. Batliboi was approved at the same board meeting as the upside payout.
General Counsel exit. K. Ramakrishnan resigned after 19 years, effective 31 March 2026 — announced 13 March, four days after the Viridity bulk-deal sale. No public reason stated.
Board composition (as of latest available filings):
Key insider transaction summary (since IPO listing):
The named promoters (Ajay Bhardwaj, Ishaan Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, family trusts) have not sold since the IPO. Promoter holding has been essentially flat at 74.67–74.69% across Sep'25 → Mar'26.
Industry Context
Beyond the company-specific findings above, three pieces of external industry evidence change the read on Anthem's positioning.
BIOSECURE / China-plus-one realignment is now legislatively concrete. S.3469's inclusion in the Senate-passed FY2026 NDAA means BIOSECURE is no longer a 2024-style stand-alone bill that died in committee — it is bundled into must-pass defense authorization legislation with a three-year FAR implementation horizon and five-year grandfathering. WuXi AppTec's customer comments in their own FY2026 results have repeatedly cited "loss of US sponsor work" — the share of that work is now actively being redirected, and Indian CRDMOs with NCE+NBE breadth (Anthem, Syngene, Divi's, Laurus, Sai Life, Aragen, Cohance) are the principal beneficiaries. Source: Hogan Lovells.
Indian CRDMO industry growth premium has been re-validated. The Frost & Sullivan-sourced thesis in the RHP — Indian CRDMO growing 13.4% CAGR vs global 9.1% CAGR to $15.4B by 2029 — has held up in 2026 commentary: ICRA upgraded Anthem to Positive outlook on margin sustainability; mutual funds raised stakes; Citi's $4.06–4.82B market cap estimate (Pitchbook/IntuitionLabs) places Anthem firmly in the global CDMO leader cohort despite being only 19 years old. The R&D-spend gap (Anthem ~2% vs Syngene/Aragen 5–7%) remains the structural critique. Sources: livemint R&D critique; IntuitionLabs CDMO profile.
GLP-1 / semaglutide remains capability-evident but revenue-pending. Anthem holds the issued WO-2023105497-A1 patent on GLP-1 analogue synthesis (Dec 2021 priority) and the largest fermentation capacity (142 kL → 182 kL planned) among Indian CRDMOs. Management commentary has graduated from "PV done / ready" to "expected significant contributor pending regulatory approvals" — but no single customer DMF filing or commercial purchase order has surfaced publicly. The India patent expiry on semaglutide (and Anthem's stated import-substitution strategy) suggests the catalyst window is FY27, not FY26. Source: PitchBook patents.
All figures in INR (₹). Conversion notes: ₹1 crore = 10 million; FY26 = year ending 31 March 2026. Sources cited inline are external; primary filings on BSE/NSE were independently surfaced via the company's investor-relations index at anthembio.com/investors/.